PeptideScanner retained ClinicalTrials.gov record NCT07242534 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06852391 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02118467 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06042153 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06802081 at 2026-07-30T16:25:18.015Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05866029 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05782816 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.
PeptideScanner retained ClinicalTrials.gov record NCT06511076 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05760313 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was linaclotide.